News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Celgene European Panel Recommends Against Revlimid for MDS
January 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Jan 24 (Reuters) - Celgene Corp said on Thursday an advisory panel for European health regulators recommended Revlimid not be approved in Europe for myelodysplastic syndrome patients with anemia, citing safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
December 10, 2025
·
2 min read
·
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
·
1 min read
·
Heather McKenzie
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
December 9, 2025
·
2 min read
·
Heather McKenzie
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
December 9, 2025
·
2 min read
·
Tristan Manalac
